Inhibition of Cancer Cell Urokinase Plasminogen Activator by Its Specific Inhibitor PAI-2 and Subsequent Effects on Extracellular Matrix Degradation

Cancer Research

Volumn 50, Issue 15, 1990, Pages 4676-4684

  Baker, Mark S ^a   Bleakley, Pamela ^a   Woodrow, Graeme C ^b   Doe, William F ^a  

^a AUSTRALIAN NATIONAL UNIVERSITY   (Australia)

^b Biotechnology Australia   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

PLASMINOGEN ACTIVATOR; PLASMINOGEN ACTIVATOR INHIBITOR 2; RADIOISOTOPE;

ARTICLE; CELL CULTURE; COLON CARCINOMA; EXTRACELLULAR MATRIX; HUMAN; HUMAN CELL; PHENOTYPE; PRIORITY JOURNAL;

CELL LINE; COLONIC NEOPLASMS; ENDOTHELIUM, VASCULAR; EXTRACELLULAR MATRIX; HUMAN; KINETICS; PLASMINOGEN ACTIVATORS; PLASMINOGEN INACTIVATORS; PROTEIN PRECURSORS; RECOMBINANT PROTEINS; SUPPORT, NON-U.S. GOV'T; TUMOR CELLS, CULTURED; URINARY PLASMINOGEN ACTIVATOR;

EID: 0025354463     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: None     Document Type: Article

References (70)

1. Ossowski, L., and Reich, E. Antibodies to plasminogen activator inhibit human tumor metastasis. Cell, 35:611–619, 1983.
2. Kohga, S., Harvey, S. R., Weaver, R. M., and Markus, G. Localization of plasminogen activators in human colon cancer by immunoperoxidase staining. Cancer Res., 45:1787–1796, 1985.
3. Mignatti, P., Robbins, E., and Rifkin, D. B. Tumor invasion through the human amniotic membrane: requirement for a proteinase cascade. Cell, 47: 487–498, 1986.
4. Ossowski, L. In vivo invasion of modified chorioallantoic membrane by tumor cells: the role of cell surface-bound urokinase. J. Cell Biol., 107:2437–2445, 1988.
5. Ossowski, L. Plasminogen activator dependent pathways in dissemination of human tumor cells in the chick embryo. Cell, 52: 321–328, 1988.
6. Hearing, V. J., Law, L. W., Corti, A., Appella, E., and Blasi, F. Modulation of metastatic potential by cell surface urokinase of murine melanoma cells. Cancer Res., 48:1270–1278, 1988.
7. Reich, R., Thompson, E. W., Iwamoto, Y., Martin, G. R., Deason, J. R., Fuller, G. C., and Miskin, R. Effects of inhibitors of plasminogen activator, serine proteinases, and collagenase IV on the invasion of basement membranes by metastatic cells. Cancer Res., 48:3307–3312, 1988.
8. Garbisa, S., Negro, A., Kalebic, T., Pozzatti, R., Muschel, R., SaffIotti, U., and Liotta, L. A. Type IV collagenolytic activity linkage with the metastatic phenotype induced by ras transfection. Adv. Exp. Med. Biol., 233:179–186, 1988.
9. Brunner, G., Pohl, J., Erkell, L. J., Radler-Pohl, A., and Schirrmacher, V. Induction of urokinase activity and malignant phenotype in bladder carcinoma cells after transfection of the activated Ha-ras oncogene. J. Cancer Res. Clin. Oncol., 115: 139–144, 1989.
10. Sim, P. S., Stephens, R. W., Fayle, D. R., and Doe, W. F. Urokinase-type plasminogen activator in colorectal carcinomas and adenomatous polyps: quantitative expression of active and proenzyme. Int. J. Cancer, 42: 483–488, 1988.
11. Nakajima, M., Lotan, D., Baig, M. M., Carralero, R. M., Wood, W. R., Hendrix, M. J., and Lotan, R. Inhibition by retinoic acid of type IV colla-genolysis and invasion through reconstituted basement membrane by metastatic rat mammary adenocarcinoma cells. Cancer Res., 49: 1698–1706, 1989.
12. Yagel, S., Khokha, R., Denhardt, D. T., Kerbel, R. S., Parhar, R. S., and Lala, P. K. Mechanisms of cellular invasiveness: a comparison of amnion invasion in vitro and metastatic behavior in vivo. J. Natl. Cancer Inst., 81: 768–775, 1989.
13. Robbins, K. C., Summaria, L., Hsieh, B., and Shah, R. J. The peptide chains of human plasmin: mechanism of activation of human plasminogen to plasmin. J. Biol. Chem., 242: 2333–2342, 1967.
14. Liotta, L. A., Goldfarb, R. H., Brundage, R., Siegal, G. P., Terranova, V., and Garbisa, S. Effect of plasminogen activator (urokinase), plasmin, and thrombin on glycoprotein and collagenous components of basement membrane. Cancer Res., 41:4629–4636, 1981.
15. Goldfarb, R. H., Murano, G., Brundage, R., Siegal, G. P., Terranova, V., Garbisa, S., and Liotta, L. A. Degradation of glycoprotein and collagenous components of the basement membrane: studies with urokinase-type plasminogen activator, α-thrombin, and plasmin. Semin. Thromb. Hemostasis, 12: 335–336, 1986.
16. Salo, T., Liotta, L. A., Keski-Oja, J., Turpeenniemi-Hujanen, T., and Tryggvason, K. Secretion of basement membrane collagen degrading enzyme and plasminogen activator by transformed cells—role in metastasis. Int. J. Cancer, 30:669–673, 1982.
17. Blasi, F., Stoppelli, M. P., and Cubellis, M. V. The receptor for urokinase-plasminogen activator. J. Cell. Biochem., 32:179–186, 1986.
18. Nielsen, L. S., Kellerman, G. M., Behrendt, N., Picone, R., Dano, K., and Blasi, F. A 55,000–60,000 Mr receptor protein for urokinase-type plasminogen activator. Identification in human tumor cell lines and partial purification. J. Biol. Chem., 263: 2358–2363, 1988.
19. Fibbi, G., Dini, G., Pasquali, F., Pucci, M., and Del Rosso, M. The Mr 17,500 region of the A chain of urokinase is required for interaction with a specific receptor in A431 cells. Biochim. Biophys. Acta, 885:301–308,1986.
20. Plow, E. F., Freaney, D. E., Plescia, J., and Miles, L. A. The plasminogen system and cell surfaces: evidence for plasminogen and urokinase receptors on the same cell type. J. Cell Biol., 103:2411–2420, 1986.
21. Estreicher, A., Wohlwend, A., Belin, D., Schleuning, W. D., and Vassalli, J. D. Characterization of the cellular binding site for the urokinase-type plasminogen activator. J. Biol. Chem., 264:1180–1189, 1989.
22. Stoppelli, M. P., Tacchetti, C., Cubellis, M. V., Corti, A., Hearing, V. J., Cassani, G., Appella, E., and Blasi, F. Autocrine saturation of pro-urokinase receptors on human A431 cells. Cell, 45:675–684, 1986.
23. Boyd, D., Florent, G., Kim, P., and Brattain, M. Determination of the levels of urokinase and its receptor in human colon carcinoma cell lines. Cancer Res., 48: 3112–3116, 1988.
24. Ng, R., Wong, A., and Kellen, J. A. Localization of plasminogen activators) in primary and secondary rat adenocarcinoma cells. Clin. Exp. Metastasis, 3: 73, 1985.
25. Skriver, L., Larsson, L. I., Kielberg, V., Nielsen, L. S., Andresen, P. B., Kristensen, P., and Dano, K. Immunocytochemical localization of urokinase-type plasminogen activator in Lewis lung carcinoma. J. Cell Biol., 99: 752–757, 1984.
26. Birkedal-Hansen, H., Birkedal-Hansen, B., Windsor, L. J., Lin, H. Y., Taylor, R. E., and Moore, W. G. Use of inhibitory (anti-catalytic) antibodies to study extracellular proteolysis. Immunol. Invest., 18: 211–224, 1989.
27. Sprengers, E. D., and Kluft, C. Plasminogen activator inhibitors. Blood, 69: 381–387, 1987.
28. Kruithof, E. K. O. Plasminogen activator inhibitors—a review. Enzyme, 40: 113–121,1988.
29. Kawano, T., Morimoto, K., and Uemura, Y. Urokinase inhibitor in human placenta. Nature (Lond.), 217: 253, 1968.
30. Lecander, I., Roblin, R., and Astedt, B. Differential inhibition of two molecular forms of melanoma cell plasminogen activator by a placental inhibitor. Br. J. Haematol., 57:407–412, 1984.
31. Wun, T. C., and Reich, E. An inhibitor of plasminogen activator from human placenta. J. Biol. Chem., 262: 3636–3653, 1987.
32. Golder, J. P., and Stephens, R. W. Minactivin: a human monocyte product which specifically inactivates urokinase-type plasminogen activator. Eur. J. Biochem., 136: 517–522, 1983.
33. Stephens, R. W., and Golder, J. P. Novel properties of human monocyte plasminogen activator. Eur. J. Biochem., 139: 253–259, 1984.
34. Genton, C., Kruithof, E. K. O., and Schleuning, W-D. Phorbol ester induces the biosynthesis of glycosylated and nonglycosylated plasminogen activator inhibitor 2 in high excess over urokinase-type plasminogen activator in human U-937 lymphoma cells. J. Cell Biol., 104: 705–712, 1987.
35. Ye, R. D., Ahern, S. M., Le Beau, M. M., Lebo, R. V., and Sadler, J. E. Structure of the gene for human plasminogen activator inhibitor 2. The nearest mammalian homologue of chicken ovalbumin. J. Biol. Chem., 264: 5495–5502, 1989.
36. Vogelstein, B., Fearon, E. R., Hamilton, S. R., Kern, S. E., Preisinger, A. C., Leppert, M., Nakamura, Y., White, R., Smits, A. M. M., and Bos, J. L. Genetic alterations during colorectal-tumor development. N. Engl. J. Med., 319: 525–532, 1988.
37. Deutsh, D. G., and Mertz, E. T. Plasminogen: purification from human plasma by affinity chromatography. Science (Wash. DC), 170: 1095–1096, 1970.
38. Lee, S. K., Singh, J., and Taylor, R. B. Subclasses of T-cells with different sensitivities to cytotoxic antibody in the presence of anesthetics. Eur. J. Immunol., 5: 259–262, 1975.
39. Coleman, P. L., and Green, G. D. J. A sensitive, coupled assay for plasminogen activator using a thiol ester substrate for plasmin. Ann. NY Acad. Sci., 570:617–626, 1981.
40. Granelli-Piperno, A., and Reich, E. A study of proteases and protease-inhibitor complexes in biological fluids. J. Exp. Med., 148: 223–234, 1978.
41. Andreasen, P. A., Nielsen, L. S., Kristensen, P., Grandahl-Hansen, J., Skriver, L., and Dano, K. Plasminogen activator inhibitor from human fibrosarcoma cells binds urokinase-type plasminogen activator, but not its proenzyme. J. Biol. Chem., 261: 7644–7651, 1986.
42. Leung, K.-C., Byatt, J. A., and Stephens, R. W. Poly-L-lysine dependent inactivation of tissue plasminogen activator by a class PAI-2 inhibitor (minactivin). Thromb. Res., 46:161–711, 1987.
43. Stephens, R. W., Pollanen, J., Tapiovaara, H., Leung, K. C., Sim, P. S., Salonen, E. M., Rönne, E., Behrendt, N., Dano, K., and Vaheri, A. Activation of pro-urokinase and plasminogen on human sarcoma cells: a proteolytic system with surface-bound reactants. J. Cell Biol., 108:1987–1995, 1989.
44. Stephens, R. W., Fordham, C. J., and Doe, W. F. Proenzyme to urokinase-type plasminogen activator in human colon cancer: in vitro inhibition by monocyte minactivin after proteolytic activation. Eur. J. Cancer Clin. Oncol., 25:213–222,1987.
45. Pollanen, J., Stephens, R., Salonen, E. M., and Vaheri, A. Proteolytic mechanisms operating at the surface of invasive cells. Adv. Exp. Med. Biol., 233: 187–199, 1988.
46. Zucker, S., Beck, G., DiStefano, J. F., and Lysik, R. M. Role for different cell proteinases in cancer invasion and cytolysis. Br. J. Cancer, 52:223–232, 1985.
47. Vlodavsky, I., Eldor, A., Bar-Ner, M., Fridman, R., Cohen, I. R., and Klagsbrun, M. Heparan sulfate degradation in tumor cell invasion and angiogenesis. Adv. Exp. Med. Biol., 233: 201–210, 1988.
48. Sloane, B. F., and Honn, K. V. Cysteine proteinases and metastasis. Cancer Metastasis Rev., 5: 249–263, 1984.
49. Zeydel, M., Nakagawa, S., Biempica, L., and Takahashi, S. Collagenase and elastase production by mouse mammary adenocarcinoma primary cultures and cloned cells. Cancer Res., 46:6438–6445, 1986.
50. Ostrowski, L. E., Ahsan, A., Suthar, B. P., Pagast, P., Bain, D. L., Wong, C., Patel, A., and Schultz, R. M. Selective inhibition of proteolytic enzymes in an in vivo mouse model for experimental metastasis. Cancer Res., 46: 4121–4128, 1986.
51. Persky, B., Ostrowski, L. E., Pagast, P., Ahsan, A., and Schultz, R. M. Inhibition of proteolytic enzymes in the in vitro amnion model for basement membrane invasion. Cancer Res., 46: 4129–4134, 1986.
52. Yagel, S., Warner, A. H., Nellans, H. N., Lala, P. K., Waghorne, C., and Denhardt, D. T. Suppression by cathepsin L inhibitors of the invasion of amnion membranes by murine cancer cells. Cancer Res., 49: 3553–3557, 1989.
53. Goldfarb, R. H., and Liotta, L. A. Proteolytic enzymes in cancer invasion and metastasis. Semin. Thromb. Hemostasis, 12:294–307, 1986.
54. Mullins, D. E., and Rohrlich, S. T. The role of proteinases in cellular invasiveness. Biochim. Biophys. Acta, 695: 177–214, 1983.
55. Collen, D. On the regulation and control of fibrinolysis. Thromb. Haemostasis,45:77, 1980.
56. Knudsen, B. S., Silverstein, R. L., Leung, L. L., Harpel, P. C., and Nachman, R. L. Binding of plasminogen to extracellular matrix. J. Biol. Chem., 261: 10765–10771, 1986.
57. Salonen, E.-M., Zitting, A., and Vaheri, A. Laminin interacts with plasminogen and its tissue-type activator. FEBS Lett., 172: 29–32, 1984.
58. Salonen, E-M., Saksela, O., Vartio, T., Vaheri, A., Nielsen, L. S., and Zeuthen, J. Plasminogen and tissue-type plasminogen activator bind to immobilized fibronectin. J. Biol. Chem., 260: 12302–12307, 1985.
59. Bergman, B. L., Scott, R. W., Bajpai, A., Watts, S., and Baker, J. B. Inhibition of tumor-cell-mediated extracellular matrix destruction by a fibroblast proteinase inhibitor, protease nexin I. Proc. Natl. Acad. Sei. USA, 83: 996–1000, 1986.
60. Brown, C. R., and Hartree, E. F. Effects of acrosin inhibitor on the soluble and membrane-bound forms of ram acrosin, and a reappraisal of the role of the enzymes in fertilisation. Hoppe-Seyler's Z. Physiol. Chem., 357: 57–65, 1976.
61. Chapman, H. A., Varin, Z., and Hibbs, J. B. Macrophage fibrinolytic activity: Identification of two pathways of plasmin formation by intact cells and of a plasminogen activator inhibitor. Cell, 28:653–662, 1982.
62. Leung, K.-C. The regulation of plasminogen activators by human minactivin, a plasminogen activator inhibitor (PAI-2). PhD Dissertation. Canberra, Australia: Australian National University, 1987.
63. Thorsen, S., Philips, M., Selmer, J., Lecander, I., and Astedt, B. Kinetics of inhibition of tissue-type and urokinase-type plasminogen activator inhibitor type 1 and type 2. Eur. J. Biochem., 175: 33–39, 1988.
64. Lucas, M. A., Straight, D. L., Fretto, L. J., and McKee, P. A. The effects of fibrinogen and its cleavage product on the kinetics of plasminogen activation by urokinase and subsequent plasmin activity. J. Biol. Chem., 258: 12171–12177, 1983.
65. Davies, J. T., and Rideal, E. K. In: Interfacial Phenomenon. New York: Academic Press, 1963.
66. Gallick, G. E., Kurzrock, R., Kloetzer, W. S., Arlinghaus, R. B., and Gutter-man, J. U. Expression of p21ras in fresh primary and metastatic colorectal tumors. Proc. Natl. Acad. Sci. USA, 82: 1795–1799, 1985.
67. Testa, J. E., Medcalf, R. L., Cajot, J. F., Schleuning, W. D., and Sordat, B. Urokinase-type plasminogen activator biosynthesis is induced by the EJ-Ha-ras oncogene in CL26 mouse colon carcinoma cells. Int. J. Cancer., 43:816–822, 1989.
68. Spinucci, C., Zucker, S., Wieman, J. M., Lysik, R. M., Imhof, B., Rama-murthy, N., Liotta, L. A., and Nagase, H. Purification of a gelatin-degrading type IV collagenase secreted by ras oncogene-transformed fibroblasts. J. Natl. Cancer Inst., 80: 1416–1420, 1988.
69. Garbisa, S., Pozzatti, R., Muschel, R. J., Saffiotti, U., Ballin, M., Goldfarb, R. H., Khoury, G., and Liotta, L. A. Secretion of type IV collagenolytic protease and metastatic phenotype: induction by transfection with c-Ha-ras but not c-Ha-ras plus Ad2-Ela. Cancer Res., 47: 1523–1528, 1987.
70. Kruithof, E. K. O., Gudinchet, A., and Bachmann, F. Plasminogen activator inhibitor 1 and plasminogen activator inhibitor 2 in various disease states. Thromb. Haemostasis, 59: 7–12, 1988.